Brief: Aligos Therapeutics Announces First Interim Analysis Results From The Phase 2 B-Supreme Study Of Pevifoscorvir Sodium In Participants With Chronic Hepatitis B Virus Infection And Grant Of FDA Fast Track Designation
14/04/2026 21:09
April 14 (Reuters) - Aligos Therapeutics Inc ALGS.O: ALIGOS THERAPEUTICS ANNOUNCES FIRST INTERIM ANALYSIS RESULTS FROM THE PHASE 2 B-SUPREME STUDY OF PEVIFOSCORVIR SODIUM IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION AND GRANT OF FDA FAST TRACK DESIGNATION ALIGOS THERAPEUTICS INC - STUDY DRUGS WELL-TOLERATED WITH NO CLINICALLY CONCERNING ABNORMALITIES ALIGOS THERAPEUTICS INC - RECEIVES FDA FAST TRACK DESIGNATION FOR PEVIFOSCORVIR SODIUM FOR CHRONIC HEPATITIS B ALIGOS THERAPEUTICS INC - TOPLINE DATA EXPECTED IN 2027; GUIDANCE REMAINS UNCHANGED ALIGOS THERAPEUTICS INC - DSMB RECOMMENDS STUDY CONTINUATION WITH INCREASED SAMPLE SIZE; FUTILITY CRITERIA NOT MET Source text: ID:nGNX3H55Fx Further company coverage: ALGS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue